Previous studies have demonstrated that naturally phosphorylated PRL antagonizes the growth-promoting effects of unmodified PRL in two different PRL-responsive cell lines. In this study our aim was to produce a molecular mimic of phosphorylated PRL by substituting a fairly bulky, negatively charged amino acid (glutamate or aspartate) for the normally phosphorylated serine [serine 179 in human PRL (hPRL)]. In addition, because of the marked effect of phosphorylation on biological activity, we investigated the importance of the unmodified serine in the growth-promoting activity of PRL. hPRL complementary DNA was obtained from the American Type Culture Collection and subcloned into pT7-SCII after site-directed mutagenesis using the deoxyuridine approach. Proteins were expressed in Escherichia coli BL21 (DE3) and were primarily found in inclusion bodies. Agonist and antagonist activities of each serine 179 mutant were assessed using the Nb2 bioassay. Compared with standard hPRL, the recombinant wild-type was more active in the Nb2 assay, attesting to both the absence, or low level, of endotoxin contamination in preparations from these cells and the appropriate folding of the molecule. The aspartate and glutamate mutants had no intrinsic agonist activity, but both antagonized the growth-promoting activity of wild-type PRL, with the aspartate mutant proving to be a very effective antagonist. Two hundred picograms per ml of the aspartate mutant negated 75% of the growth response to 400 pg/ml wild-type PRL. When serine 179 was mutated to alanine or valine, mutant PRLs with 0% and 14% of the biological activity of wild-type PRL, respectively, were produced. These results demonstrate 1) that molecular mimicry of the phosphorylated hormone does produce a PRL antagonist, and 2) that the serine at position 179 is crucial to the growthpromoting activity of PRL. The aspartate mutant can now be used to study many aspects of the physiology of PRL. (Endocrinology 139: 609 -616, 1998) 
W E HAVE previously demonstrated that naturally phosphorylated rat PRL (rPRL) antagonizes the growth-promoting effects of unmodified PRL in 1) the Nb2 T lymphoma assay (1) and 2) the autocrine regulation of GH 3 cell proliferation (2) . Others, however, have failed to find evidence of antagonism in the Nb2 assay using isolated preparations of more negatively charged bovine PRL (bPRL), but have found that dephosphorylation of bPRL increased Nb2 biological activity (3) . With the rat hormone, we found that the ratio of unmodified to phosphorylated PRL in large part determines the response to administered hormone. At high ratios of unmodified to phosphorylated PRL, cell proliferation is promoted (1), whereas at low ratios, proliferation is inhibited (1, 2) and, in the case of GH 3 cells, differentiation is promoted (4) . The ratio of unmodified to phosphorylated PRL produced by the pituitary varies reproducibly according to the stage of the estrous cycle (5) and during pregnancy and pseudopregnancy (6) , with elevations in estrogen producing a more mitogenic PRL (5, 6) .
To further investigate the functions of phosphorylated PRL and the mechanism by which it antagonizes the unmodified form, we set out to determine whether mutation of the normally phosphorylated serine to an acidic residue of similar mass to phosphoserine, would produce a molecular mimic of phosphorylated PRL. Previous work from our laboratory has demonstrated that rPRL is primarily phosphorylated on serine 177 (7), which is an absolutely conserved residue in all PRLs in a very highly conserved region of the molecule (8) . The equivalent residue in human PRL (hPRL) is serine 179 (8) . Because of the potential therapeutic value of a PRL antagonist, we chose to make recombinant hPRL rather than rPRL mutants. Thus, serine 179 in hPRL was mutated to either glutamate or aspartate.
In addition, because of the dramatic effect of phosphorylation of serine 177/179 on biological activity, we determined the importance of the unmodified serine on the growthpromoting activity of PRL. This was accomplished by mutating the serine to two neutral amino acids of reasonably similar size to serine: alanine and valine.
We report the production of a highly effective antagonist by mutation of serine 179 to aspartate, and in so doing reconfirm the importance of phosphorylation at this site. In addition, it appears that the serine 179 residue in the unmodified molecule is crucial to the growth-promoting activity of PRL.
Materials and Methods

Subcloning and site-directed mutagenesis
The hPRL complementary DNA clone (pBR-hPRL) was obtained from the American Type Culture Collection (Rockville, MD). A 686-bp PpuMI fragment, which contained the full hPRL-coding region, was subcloned into the SmaI site of pUC118 (U.S. Biochemical Corp., Cleveland, OH) in which the BamHI site was nullified. This recombinant was transformed into Escherichia coli CJ236 cells, which produce deoxyuridine (dU)-containing single-stranded DNA after infection with M13K07 helper phage and incubation in 0.25 g/ml uridine.
Site-directed mutagenesis was performed using a Muta-Gene in vitro mutagenesis kit (Bio-Rad, Hercules, CA). One primer (ACGCAGGGAT-GNKATAAAATCG) was designed to substitute serine 179 with glutamate, aspartate, alanine, or valine. A second primer (CGTGGC-CCCCATATGTTGCCCATCTG) was used to facilitate cloning into an expression vector via the production of an NdeI site. Appropriate mutations were confirmed by sequencing. Mutated DNA was subcloned into pT7-SCII (U.S. Biochemical Corp.), which was placed into E. coli BL21 (DE3) for protein expression.
Protein expression
Cells were cultured in Luria broth with ampicillin (200 g/ml) overnight at 37 C. The overnight culture was diluted 10 times in the same medium, aliquoted into 3-ml amounts, and incubated at 37 C with agitation until the OD 600 nm reached 0.55-0.6. Isopropyl ␤-thiogalactoside (final concentration, 0.5 mm) was added to the culture to induce expression of the protein. Optimizing experiments determined that the best yield coupled to the best purity was obtained after a 2-h induction. The bacteria (3 ml) were pelleted and resuspended in 500 l ice-cold 50 mm Tris-HCl, pH 7.5. They were then lysed using a MicroUltrasonic cell disrupter (Kontes, Plainview, NJ) (five 15-sec pulses at setting 9 on ice, with a 30-sec pause between pulses) and then centrifuged at 14,000 ϫ g for 10 min at 4 C.
Expressed PRLs were primarily in inclusion bodies that formed the 14,000 ϫ g pellet. After washing in ice-cold 50 mm Tris-HCl, pH 7.5, they were denatured in 8 m urea-1% ␤-mercaptoethanol in 0.2 m sodium phosphate, pH 7, and the resulting solution was dialyzed against 20 vol 50 mm NH 4 HCO 3 , with eight changes in 3 days at 4 C, with a final protein concentration of 0.1 mg/ml.
The amount of protein present was determined either by quantitative gel densitometry by comparison to hPRL standards or by using the NanoOrange kit (Molecular Probes, Eugene, OR). In the latter instance, NIDDK hPRL B-3 was dissolved in 50 mm NH 4 HCO 3 and serially diluted to produce the reference standard curve. Both methods gave comparable results. Highly purified BSA (Sigma Chemical Co., St. Louis, MO) was added (to 0.05%) as soon as possible to reduce recombinant protein losses caused by adherence or proteolysis.
RIA analysis of the recombinant PRLs
Recognition of the mutant PRLs compared with two standard NIDDK PRLs, hPRL I-8 and rPRL B7, in a commercially available RIA was used as a measure of appropriate folding. Each protein was dissolved first in 50 mm NH 4 HCO 3 , accurately quantified, and then diluted in the O calibrator provided with the kit. The kit was purchased from Diagnostic Products Corp. (Los Angeles, CA).
Endotoxin analysis of the preparations
Endotoxin contamination of the PRLs was first tested using the E-TOXATE kit from Sigma and by gel analysis for bacterial lysate endotoxins (9) . Briefly, for the latter, proteinase K-deproteinated samples were run on a 14% SDS reducing polyacrylamide gel and then silver stained to detect endotoxin bands.
Preparations were also tested for toxicity at concentrations up to 0.5 g/ml by analyzing changes in cell proliferation over a 72-h period in bone SaOs cells (American Type Culture Collection).
In addition, parallel preparations of the various mutants and the wild-type PRL were made so that on each occasion the wild-type PRL could be analyzed for biological activity relative to the other preparations as well as to NIDDK standards in the Nb2 bioassay.
Dephosphorylation of standard hPRL
Standard hPRL I-8 was exposed to acid phosphatase (from human semen; Sigma) at a ratio of 10 g to 1 U enzyme in 0.1 m sodium citrate buffer, pH 5, for 2 h at 37 C. Control aliquots of the hormone alone and enzyme alone were incubated in buffer for the same period and at the same temperature. After 2 h of incubation, the samples were diluted 40-fold in Dulbecco's PBS (DPBS) containing 0.1% BSA (highly purified from Sigma). Each sample (enzyme-treated, buffer-incubated, and enzyme in buffer) was sterilized by filtration and stored frozen at Ϫ20 C until further dilution in 0% FBS-10% horse serum (HS)-Nb2 assay medium.
Biological activity of the wild-type, mutant PRLs and dephosphorylated NIDDK standard PRL
The Nb2 bioassay was performed as described by Tanaka et al. (10) . Briefly, Nb2 T lymphoma cells (originally obtained from Henry Friesen, now at Medical Research Council, Ottawa, Canada) were maintained in Fisher's medium containing 10% FBS, 10% HS, 0.1 mm NaHCO 3 , 0.1 mm ␤-mercaptoethanol, and penicillin (20 U/ml)/streptomycin (20 g/ml). Before the assay, cells were transferred to 1% FBS-10% HS medium overnight. The cells were then plated onto 96-well plates in 100 l 0% FBS-10% HS medium/well. Different concentrations and combinations of PRLs, diluted in 0% FBS-10% HS medium, were added to give a total volume of 200 l/well. For measurement of proliferation, 5000 cells/ well were used. For studies of antagonism, 1000 cells/well were used to increase competition for the receptors. The number of cells required to produce receptor-limiting conditions during a 3-day incubation was determined empirically. In each experiment (5000 or 1000 cells/well), the response to wild-type PRL alone was used as a positive control and a measure of comparability among experiments. Cell number was assessed 72 h after plating using an MTS assay (1, 11) . Briefly, MTS dye
Corp., Madison, WI] at 2 mg/ml in DPBS was mixed with phenazine methosulfate (Sigma; 0.92 mg/ml DPBS) at a ratio of 20:1 (vol/vol). Twenty microliters of the mixture were then added to the 200 l medium in each well, and the plate was incubated for 2 h at 37 C before reading the absorbance at 492 nm in an enzyme immunoassay plate reader (Bio-Rad). Results are expressed as the absorbance in the test wells minus the absorbance in the wells containing cells but no added PRL.
Within each assay, each test substance, combination, or amount was assayed in quadruplicate. Each assay result was replicated at least twice with each preparation of protein, and each result was replicated with at least two, and in most instances three, separate preparations of protein. although losses during processing were slightly greater for the glutamate and aspartate mutants, a result perhaps attributable to the small increase in negative charge on these molecules. Based on densitometric scans of Coomassie bluestained gels, the purity of the PRL preparations was greater than 95% when using a 2-h induction period with isopropyl ␤-thiogalactoside. Longer induction periods led to an increase in higher mol wt contaminants in the inclusion bodies with no significant increases in final yield. Nonreducing gels showed no evidence of oligomeric forms after folding (data not shown).
Results
Protein purity
Because our aim was to develop an antagonist, it was important to demonstrate that antagonism in our recombinant preparations was not due to endotoxin contamination. The two most frequently used assays for endotoxin contamination (gel analysis and E-Toxate), however, did not prove very useful. Neither showed any evidence of endotoxin, but gel analysis is not very sensitive, and the recombinant proteins themselves interfered with gelation in the E-Toxate assay, so this assay was not conclusive. It was, therefore, important to develop alternate methods of assessment of endotoxin contamination. The first of these was analysis of general toxic effects of the preparation on a PRL-unresponsive cell line, SaOs cells. The recombinant proteins, up to concentrations of 0.5 g/ml (i.e. 1000-fold the concentrations used in the Nb2 bioassays), had no effect on cell proliferation (data not shown). In addition, we developed a standard procedure by which at least wild-type and one other and usually all recombinant proteins were expressed, isolated, and folded in parallel. As all of the proteins are expressed in the same bacteria, parallel expression and purification should ensure equivalent contamination with any non-PRL factors with either a positive or negative effect on Nb2 cell proliferation. Thus, if there were any non-PRL antiproliferative substance in the glutamate and aspartate mutants, they should also be present in the alanine, valine, and wild-type preparations. Likewise, any non-PRL proliferative substances in the wild-type preparation should also be present in the glutamate, aspartate, and alanine preparations. As, for example, the wild-type preparation has such high proliferative activity and the aspartate and glutamate mutants have none, it seems unlikely that the preparations contain either proliferative or antiproliferative activity besides that inherent to the PRL molecules.
Biological activity
As can be seen in Fig. 2 , the recombinant wild-type PRL had greater biological activity in the Nb2 bioassay than did the NIDDK hPRL B-3 preparation. This result attests to 1) the absence, or very low levels, of endotoxin in the preparation; and 2) appropriate folding of the molecule during the dialysis period. Accurate comparisons were assured by dissolution of the NIDDK standard in 50 mm NH 4 HCO 3 and the use of this to produce both the bioassay stock and the standard curve in the NanoOrange protein assay.
NIDDK PRL is extracted from pituitaries and contains a mixture of nonphosphorylated and phosphorylated forms of the hormone (12, 13) in addition to at least one glycosylated form (14) . As phosphorylated PRL acts as an antagonist to nonphosphorylated PRL in the Nb2 bioassay, its presence reduces the Nb2 response (1). In addition, glycosylated PRL has been shown to have about one third to one fourth the biological activity of unmodified PRL (15) , and the B3 preparation contains about 25% glycosylated PRL based on analysis of gels similar to the one shown in Fig. 1 . Recombinant wild-type hormone produced in E. coli, by contrast, contains no phosphorylated or glycosylated hormone, and hence, a larger proliferative response to a recombinant preparation can be obtained.
That some of the increased activity is probably due to the absence of phosphorylated hormone in the recombinant wild-type PRL is demonstrated in Fig. 3 . For this experiment, a similar preparation of human pituitary PRL, hPRL I-8, which has less than 10% phosphorylated hormone, was subjected to dephosphorylation by acid phosphatase. As can be seen, dephosphorylation of the I-8 preparation increased its ability to stimulate the proliferation of Nb2 cells. Assay of enzyme alone showed no ability to stimulate Nb2 cell proliferation (data not shown).
The results presented in Figs. 2 and 3 and the wild-type curves in Figs. 4 and 5 also show evidence of PRL self antagonism at high concentrations (16) . Unlike the report by Goffin et al. (16) , however, this self antagonism was observed using human hormone and rat cells. In other experiments, using doses up to only 1000 pg/ml (Figs. 6 and 7) , self antagonism was not reached. The degree of self antagonism observed was related to the dose necessary for the peak response, which varied among different sets of cells. Despite all attempts to standardize all apparent possible variables in the cultures, some variation in peak response (400 or 800 pg/ml) still persisted.
Glutamate and asparate mutants
Substitution of serine 179 with aspartate or glutamate produced a molecule that acted as an antagonist (Fig. 4, A and  B) . When either was titrated against the wild-type recombinant, a dose-related inhibition of proliferation vs. wild-type PRL alone was observed. The aspartate mutant was a more potent antagonist than the glutamate mutant, with 200 pg/ml aspartate mutant inhibiting the growth response to 400 pg/ml wild-type PRL by 75%. In both instances the mutants showed titration curves apparently consistent with noncompetitive inhibition (see Discussion).
When tested alone for intrinsic agonist activity, neither the aspartate nor the glutamate mutant showed any ability to stimulate Nb2 cell proliferation (Fig. 5) .
Importance of serine 179 to bioactivity
Because of the major effects of phosphorylation on the proliferative activity of PRL and its mimicry by the substitution of glutamate or aspartate at serine 179, we examined the role of serine 179 itself in producing proliferative activity. This was accomplished by conservatively mutating it to either alanine or valine. Contrary to our initial expectations, the alanine mutant was essentially without biological activity, whereas the valine mutant proved to be a mild agonist (Fig. 6 ). When titrated with recombinant wild type PRL, no additive proliferative activity was seen for the alanine mutant, but some additive proliferative activity was seen at low concentrations of wild-type PRL for the valine mutant (Fig.  7, A and B) . When the alanine and valine mutants were titrated with wild-type under receptor-limiting conditions (i.e. using 1000 cells/well), both were found to be mild antagonists, indicating that they could bind to the receptor to some degree (data not shown). Figure 8 illustrates the cross-reactivity of an anti-hPRL antibody with the recombinant proteins and with NIDDK standard human and rat PRL. The degree of antibody recognition can be used as a monitor of three-dimensional structure and, therefore, provides some measure of appropriate molecular folding. As can be seen, the aspartate mutant, the NIDDK standard, hPRL I-8, the alanine mutant, and the assay standard were all very similarly recognized. This suggests that they each have average conformations that are very similar. The valine mutant and wild-type proteins were recognized somewhat more efficiently by the antibody, and the glutamate mutant was recognized much less efficiently, suggesting changes in conformation vs. that of the assay standard. According to the manufacturers, the assay standards were normal preparations of circulating PRL, containing posttranslationally modified forms. As can be seen, the assay is also fairly sensitive to structural changes, as it was entirely unable to recognize rPRL at concentrations up to 200 ng/ml.
RIA analysis
Discussion
While two groups have previously investigated the effect of one or more amino acid substitutions on the Nb2 mito- genic activity of the PRLs produced (8, (17) (18) (19) (20) (21) ; reviewed in Ref. 22) , no one has previously mutated hPRL serine 179 or its equivalent in other species. It has been deleted with subsequent loss of biological activity (18) , but given the likely effect of this deletion on the conformation of an important helix, this result is hard to interpret. Residues very close to this serine, including the arginine at Ϫ2 and the lysine at ϩ2, have been shown to be crucial for tight binding to the receptor. Thus, when either residue was mutated to alanine, Nb2 receptor binding (19) was reduced to 1% or less of wild-type binding. Even a conservative change in the Ϫ2 arginine to a lysine reduced the biological activity by 90% (18) . Thus, this appears to be a very sensitive region of helix 4, necessary either for direct interaction with the receptor or for structural stabilization of the molecule so that optimal ligand-receptor interactions can occur.
With the substitution of alanine for serine, we expected very little effect on agonist activity. To our surprise this substitution negated essentially all agonist activity. The RIA results attest to appropriate folding of the alanine-substituted molecule. It appears, therefore, that the serine is crucial for appropriate PRL-receptor interactions. Substitution of another neutral, but somewhat more bulky than alanine, amino acid (valine) produced a partial agonist. It seems likely, therefore, that the physical bulk of the serine is of significance as is perhaps the hydroxyl moiety.
When this serine is phosphorylated, an antagonist to nonphosphorylated PRL is produced (1). When phosphoserine was mimicked in the present study by mutating the serine to glutamate or aspartate, an antagonist was also the result. In the case of naturally phosphorylated PRL, titrations and dephosphorylation experiments have shown that relatively low percentages of phosphorylated PRL are required to negate the proliferative activity of nonphosphorylated PRL (1). Likewise, the aspartate mutant is a more potent antagonist than the wild type is an agonist. The mechanisms by which this relative potency may be achieved are varied, in part because what is being measured in an Nb2 bioassay is cell number at the end of a 3-day incubation. During the 3-day incubation, several doublings have taken place, and PRL receptors have recycled to the cell surface many times. Included in the possibilities are a significantly higher affinity of the aspartate mutant for the receptor or both receptors, induction of apoptosis by the aspartate mutant, or inhibition of signal amplification by the aspartate mutant (see below). However the potency of the aspartate antagonist is achieved, it is apparently not due to a major ligand conformational change, as the aspartate mutant is seen as readily in the RIA as the assay standard. The glutamate mutant, on the other hand, has a significantly altered conformation that may well affect binding to a second receptor.
Both the glutamate and aspartate mutants show titration curves consistent with noncompetitive inhibition, i.e. increased concentrations of wild-type do not overcome the inhibition. This apparent noncompetitive inhibition, however, is probably due to the self antagonism of the wild type, i.e. when more agonist is added past the peak response, a significant amount of this will be producing one to one wildtype to receptor complexes and not one to two signal transducing complexes.
The mechanism by which phosphorylated PRL or its mimic acts as an antagonist is unknown. To date, antagonists for GH and PRL have been designed by mutating a region of these molecules involved in the binding of a second receptor, thus preventing receptor dimerization and signal transduction (16, 23) . Serine 179 is in the region of the molecule that forms site 1 (22) , and it is not immediately obvious how it might affect site 2 binding, if, in fact, it does. The conformational changes that could result from a bulky phosphate group, however, may well affect relatively distant parts of the molecule. When one creates a helical wheel representation (24) of helix 4 ( Fig. 9) and makes the assumption that residues found critical to biological activity by others directly participate in receptor binding (R177, K181, and K187) (18, 19) , then one can appreciate that serine 179 lies on the opposite side of the helix. In the model of Goffin et al. (22) this would face helix 3. If it stays in this orientation after phosphorylation, then it could well affect helix 3 orientation and, hence, site 2 binding. However, the presence of a large phosphate group in the hydrophobic interior of a molecule seems unlikely. It seems more likely that phosphorylation significantly changes the orientation of helix 4 and the way it interacts with the receptor. Perhaps the altered conformation of the receptor under these circumstances prevents signal transduction and amplification. If the second receptor has a fast on and off rate, as Gertler has demonstrated it has in homologous systems (25) , and the one-receptor one-ligand complex, therefore, interacts with multiple second receptors to amplify the signal, the inability to amplify the signal with the phosphorylated hormone/aspartate mutant may account for the apparent potency of the antagonist. This possibility remains the subject of future investigations. In this regard, there is precedent for the production of members of the PRL family that can bind to, but not activate, the PRL receptor (26, 27) .
Other investigators have successfully produced PRL antagonists (16, 23) , but none reported to date is as potent as the glutamate or aspartate mutants. Thus, the hGH G120R mutant of Fuh and Wells (23) has an IC 50 6-fold that of the wild-type PRL agonist, and the best mutants described by Goffin et al. (16) have an IC 50 10-fold that of the agonist using a rat receptor. The aspartate mutant we have described has an IC 50 0.25-fold that of the agonist. In other words, 100 pg/ml of the aspartate mutant inhibits proliferation induced by 400 pg/ml wild-type PRL by 50% (data not shown). What is shown in the figures is 75% inhibition by 200 pg/ml. Molecular mimicry of phosphorylation has been successfully applied to a variety of enzymes turned constitutively on or off by phosphorylation (28 -30) . In one instance, the structural changes observed after phosphorylation have also been shown to be accurately reproduced by an aspartate mutant (31) .
Molecular mimicry of phosphorylated PRL has been claimed before, but for the bovine hormone (32) . In this instance, serine 90 in bPRL, a site previously shown to be posttranslationally modified (33) was mutated to glutamate. When mutated to glutamate, the resultant bPRL, like preparations of phosphorylated bPRL, had reduced ability to stimulate Nb2 cell proliferation (32) . This, however, is true of many single amino acid substitutions in bPRL (18) . In the current manuscript, we describe the production of a molecular mimic of the phosphorylated hormone, which, like the phosphorylated hormone, very effectively antagonizes growth promotion in response to unmodified hormone. This positive measure of activity is a stronger indication of mimicry.
The production of a recombinant mimic of the phosphorylated hormone has several advantages. First, it can relatively easily be produced in large quantities, entirely free of its nonphosphorylated counterpart. Second, it cannot be dephosphorylated either during in vitro or in vivo experiments, thus making interpretation of experimental data more straightforward. When potentially administered therapeutically, the mimic cannot be converted to the growth-promoting form of PRL. Although we have demonstrated that phosphorylated PRL is actually very resistant to phosphatase activity, requiring 2-to 4-h incubations (i.e. many fold the half-life of PRL in serum) in concentrated enzyme to remove the phosphate (1, 2), this advantage may be significant with slow release or extended lifetime forms of the hormone.
As it is now known that a variety of extrapituitary tissues produce PRL (reviewed in Ref. 34) and that a number of these also respond to or have the potential to respond to PRL (35) , there is growing acceptance and accumulating evidence that autocrine/paracrine PRL may contribute to the progression of certain diseases, such as breast cancer (36 -41) and lymphomas (42) . Although the secretion of all forms of PRL from the anterior pituitary is readily controlled by existing pharmaceuticals, a need is now appreciated for a PRL receptor antagonist that can negate autocrine/paracrine growth promotion in these other tissues.
In summary, we have produced a molecular mimic of phosphorylated PRL that maintains the antagonist properties of the phosphorylated hormone. This pseudophosphorylated PRL can now be used to study many aspects of the physiology of PRL and has the potential to be a useful therapeutic.
